According to Coherent Market Insights, the worldwide bipolar disorder treatment market is anticipated to be worth US$ 48.4 billion in 2020, with a CAGR of 6.6 percent during the forecast period (2020-2027).
The emphasis of key players on regulatory clearances to create a therapy for bipolar illnesses is projected to drive the growth of the global bipolar disorder treatment market during the forecast period. For example, Lupin Limited got clearance from the United States Food and Drug Administration (US FDA) in April 2019 for its Fluoxetine tablets United States Pharmacopeia (USP) of strength 60mg for the treatment of depression in adults.
North America is anticipated to dominate the worldwide bipolar disorder treatment market during the forecast period, owing to major companies concentrating on strategic alliances with governments of different low-income nations such as Africa to improve bipolar health care. Johnson & Johnson Services Inc. (Johnson & Johnson) established a strategic collaboration with the Government of Rwanda in 2019 to dramatically enhance and extend access to excellent bipolar disorder treatment in the nation.
Because to the growing incidence of bipolar illnesses worldwide, the global bipolar disorder treatment market is anticipated to grow at a CAGR of 6.6 percent during the forecast period. For example, according to a World Health Organization report published in 2019, about 45 million people worldwide suffered from bipolar bipolar disorder in 2019.
Allergan plc is a key participant in the worldwide bipolar illness treatment industry. VistaGen Therapeutics, Sanofi S.A., Novartis International AG, Mylan N.V., Amneal Pharmaceuticals LLC, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Janssen Pharmaceutica, Bristol Myers Squibb, and Sumitomo Dainippon Pharma Co., Ltd.